Compare EH & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EH | BBNX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 435.4M | 493.1M |
| IPO Year | 2019 | 2025 |
| Metric | EH | BBNX |
|---|---|---|
| Price | $5.83 | $18.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $22.47 | ★ $23.80 |
| AVG Volume (30 Days) | 637.9K | ★ 1.3M |
| Earning Date | 05-26-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 78.95 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $100,251,000.00 |
| Revenue This Year | $33.23 | $34.90 |
| Revenue Next Year | $73.83 | $34.63 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.94 |
| 52 Week Low | $4.89 | $8.80 |
| 52 Week High | $20.20 | $32.71 |
| Indicator | EH | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 53.00 | 63.68 |
| Support Level | $4.89 | $9.34 |
| Resistance Level | $6.98 | $18.20 |
| Average True Range (ATR) | 0.25 | 1.31 |
| MACD | 0.15 | 0.31 |
| Stochastic Oscillator | 93.75 | 95.44 |
EHang Holdings Ltd is an urban air mobility (UAM) technology platform company focused on autonomous aerial vehicle technology and solutions. The company provides unmanned aerial vehicle (UAV) systems and solutions for air mobility, including passenger transportation and logistics, as well as smart city management and aerial media solutions. Its EH216-S passenger-carrying pilotless eVTOL aircraft has obtained a production certificate and standard airworthiness certificate from the Civil Aviation Administration of China (CAAC).
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.